#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    PIK3CA-activated mutation Hyperinsulinism Raynaud's phenomenon Astrocytoma malignant Malignant central nervous system neoplasm Peritoneal mesothelioma malignant Mantle cell lymphoma stage II Non-renal cell carcinoma of kidney Acute graft versus host disease in skin Severe myoclonic epilepsy of infancy Haemophilia B without inhibitors Nephropathy Primary hyperoxaluria Cervix carcinoma Anaplastic thyroid cancer More trials…

    Learn about Rare Diseases

    Glomerulonephritis membranoproliferative – Diagnostics Piriformis syndrome Paraneoplastic neurological syndrome – Basic Information Rett syndrome Gaucher’s disease type III – Diagnostics KBG syndrome – Life with Disease Stevens-Johnson syndrome – Life with Disease Hairy cell leukaemia Glycogen storage disease type V – Basic Information Hepatic angiosarcoma – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Pf-06835375 Vinorelbine Revumenib L-PHENYLALANINE Tofogliflozin 7-Ethyl-10-Hydroxycamptothecin Octocog Alfa Morf-057 Magnesium Lanreotide Talazoparib Io103 Acetate Pentixafor VOROLANIB VRDN-003 ICEF15 L-ALANINE Empasiprubart Cls12311 CC-97540 More therapies…

    Learn about Your Condition

    Sleep disorder Dupuytren's contracture Mitral valve incompetence Breast cancer stage IV Seasonal allergy Pyelonephritis Angiosarcoma recurrent Fibrous dysplasia of bone Autoimmune haemolytic anaemia Osteosarcoma metastatic Lennox-Gastaut syndrome Fracture infection Vertebrobasilar stroke Heparin resistance Mite allergy More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Dementia Alzheimer’s type

  • A Study of Donanemab in People With Early Symptomatic Alzheimer’s Disease

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Dementia
    • Mental disorder
    • Neurodegenerative disorder
    Investigated Drugs:
    • Donanemab
    • Florbetapir (18F)
    • Flortaucipir (18F)
    Poland Spain

  • A Study to Test the Long-term Safety and Benefits of GSK4527226 in Patients with Early Alzheimer’s Disease

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Dementia Alzheimer’s type
    Investigated Drugs:
    • Gsk4527226
    Finland France Germany Italy The Netherlands Norway +2

  • Study of RO7126209 safety and effects given by intravenous infusion in patients with early stage or mild to moderate Alzheimer’s disease

    Not recruiting

    1 1
    Investigated Diseases:
    • Dementia Alzheimer’s type
    Investigated Drugs:
    • TRONTINEMAB
    • Flortaucipir (18F)
    Poland Spain

  • Study of microglial activation and synaptic density using [18F]-DPA-714, [18F]-Ro948, [11C]-UCB-J, and [11C]PiB PET imaging in patients with Alzheimer’s disease

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Dementia Alzheimer’s type
    Investigated Drugs:
    • (N-METHYL-(11C))2-(4′-METHYLAMINOPHENYL)-6-HYDROXYBENZOTHIAZOLE
    • 2-(6-[18F]Fluoro-Pyridin-3-Yl)-9H-Dipyrido[2,3-B:3′,4′-D]Pyrrole
    • (4R)-1-[(3-(11C)Methylpyridin-4-Yl)Methyl]-4-(3,4,5-Trifluorophenyl)Pyrrolidin-2-One
    France

  • Study on the Safety and Effects of Plasma Transfusion from Exercise-Trained Donors in Patients with Early Alzheimer’s Disease Using Human Plasma Protein and Saline

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Dementia Alzheimer’s type
    Investigated Drugs:
    • Human Plasma Protein
    • Saline
    Norway

  • Study on the Effects of Phenserine and Donepezil in Patients with Early or Mild Alzheimer’s Disease

    Not recruiting

    1 1 1 1
    Investigated Diseases:
    • Cognitive disorder
    • Dementia Alzheimer’s type
    Investigated Drugs:
    • (-)-PHENSERINE TARTRATE
    • Donepezil Hydrochloride
    Norway
Previous Page
1 … 8 9 10 11 12 … 15
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!